Nociception

Canada’s surgery backlog could lead to wave of new chronic pain and opioid dependencies

Retrieved on: 
Wednesday, July 21, 2021
Pain, Nervous system, Branches of biology, Nociception, Pain management, Acute pain, Chronic pain, Chronic condition, Surgery, Childhood chronic pain, Failed back syndrome

TORONTO, July 21, 2021 (GLOBE NEWSWIRE) -- As Canada’s vaccination rates climb and hospitals begin to tackle the mountain of postponed surgeries due to the pandemic, we are facing an echo epidemic of new chronic pain sufferers. Studies show that roughly 30 per cent of those undergoing surgery will go on to develop chronic pain, and about 25 per cent of all chronic pain conditions originate from surgical procedures.1,2 This has a detrimental effect on families, communities and the healthcare system. However, with recent innovations in genetic testing this does not have to be the fate for the thousands of Canadians who are about to have surgery.

Key Points: 
  • Studies show that roughly 30 per cent of those undergoing surgery will go on to develop chronic pain, and about 25 per cent of all chronic pain conditions originate from surgical procedures.1,2 This has a detrimental effect on families, communities and the healthcare system.
  • However, with recent innovations in genetic testing this does not have to be the fate for the thousands of Canadians who are about to have surgery.
  • The risk of chronic pain following surgery is high.
  • The risk may be further compounded by the current echo pandemic of mental health issues, as depression and anxiety significantly increase the risk of developing chronic pain after surgery.

Q-State Biosciences Awarded NIH Grant for the Development of ASO Therapies Targeting Cancer Pain

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Pharmaceutical, Health, Branches of biology, Nervous system, Pain, Sodium channels, Symptoms and signs, Nociception, Acute pain, Cancer pain, Oncology, National Institutes of Health, Nav1.7, Opioid

Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the development of antisense oligonucleotide (ASO) therapeutics for the treatment of cancer pain. Q-State will subsequently be eligible for an additional $1 million in grant funding based on successful completion of certain program milestones.

Key Points: 
  • Funded as part of the NIH HEAL InitiativeSM, the grant supports Q-States efforts to pursue analgesic treatment paradigms beyond those associated with opioids.
  • The company is currently advancing ASO candidates targeting Nav1.7, Nav1.8, or both channels using the companys AI-enabled computational neuroscience technology.
  • In addition to cancer pain, these ASO candidates also have potential applicability in the treatment of a variety of other moderate-to-severe pain states.
  • This grant was awarded by the National Institute of Cancer of the National Institutes of Health under Award Number R44CA247110.

Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Nervous system, Pain, Acute pain, Nociception, Neuropathic pain, Peripheral neuropathy, Transcutaneous electrical nerve stimulation, Nav1.8

The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.

Key Points: 
  • The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.
  • The primary endpoint in both studies is the time-weighted Sum of the Pain Intensity Difference over the first 48 hours of treatment (SPID48).
  • NaV1.8 is a genetically validated novel target for the treatment of pain, and Vertex has previously demonstrated clinical proof-of-concept with a small molecule investigational treatment targeting NaV1.8 in multiple pain indications including acute pain, neuropathic pain and musculoskeletal pain.
  • Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

Nalu Medical Announces Scientific Presentations at 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Nervous system, Medicine, Pain, Neurotechnology, Acute pain, Nociception, Neuromodulation, Neurostimulation, Nalu, Neuropathic pain, Pain management

CARLSBAD, Calif., July 15, 2021 /PRNewswire-PRWeb/ --Nalu Medical, Inc. ("Nalu"), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral presentations.

Key Points: 
  • CARLSBAD, Calif., July 15, 2021 /PRNewswire-PRWeb/ --Nalu Medical, Inc. ("Nalu"), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral presentations.
  • We are a medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain.
  • Our Nalu Neurostimulation System, or Nalu System, delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain.
  • Nalu, the Nalu logo and nPower are trademarks of Nalu Medical, Inc.
    1.

2021 Report on Ocular Pain Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Pharmaceutical, Health, Optical, Pain, Nervous system, Branches of biology, Nociception, Acute pain, Suffering

The "Ocular Pain (Eye Pain) (Central Nervous System) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ocular Pain (Eye Pain) (Central Nervous System) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Ocular Pain (Eye Pain), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain (Eye Pain) and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Ocular Pain (Eye Pain) (Central Nervous System) therapeutics and enlists all their major and minor projects.

Global Neuropathic Pain Epidemiology and Patient Flow Report 2021: Prevalence, Diagnosed, and Drug-treated Patients to 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Pharmaceutical, Nervous system, Branches of biology, Pain, Neuropathic pain, Nociception, Acute pain, Peripheral neuropathy

The "Global Neuropathic Pain Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Neuropathic Pain Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Neuropathic Pain Epidemiology and Patient Flow Analysis - 2021, provides Neuropathic Pain epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Neuropathic Pain patients, history of the disease at the population level (Neuropathic Pain prevalence, Neuropathic Pain incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Neuropathic Pain patients by age group, gender
    The data from this research will help executives:
    Establish basis for Neuropathic Pain market sizing, assessing market potential, and developing drug forecast models
    Identify Neuropathic Pain patients segments through age groups, gender, and disease sub-types
    Evaluate Neuropathic Pain market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005474/en/

Multi-Center Study of SPRINT® PNS System for Chronic Low Back Pain Demonstrates Clinically Significant Improvements in Pain and Quality of Life

Retrieved on: 
Monday, July 12, 2021
Pain, Branches of biology, Clinical medicine, Nociception, Acute pain, Suffering, Chronic pain, Back pain, Transcutaneous electrical nerve stimulation, Amputation, Shoulder problem, Occipital nerve stimulation

73 percent of participants experienced a clinically significant reduction in average pain intensity with an average reduction in pain intensity of 58 percent among this group.

Key Points: 
  • 73 percent of participants experienced a clinically significant reduction in average pain intensity with an average reduction in pain intensity of 58 percent among this group.
  • Participants also reported substantial and statistically significant improvements in secondary endpoints including changes in health-related Quality of Life (QoL), patient global impression of change, and depression.
  • The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and iscleared for use up to 60 days.
  • Our SPRINT PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain.

Global Postoperative Pain Market to 2030 - Insight, Epidemiology and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Nervous system, Branches of biology, Symptoms and signs, Nociception, Acute pain, Pain, Suffering

The "Postoperative Pain- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Postoperative Pain- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Postoperative Pain market report provides current treatment practices, emerging drugs, Postoperative Pain market share of the individual therapies, current and forecasted Postoperative Pain market Size from 2017 to 2030 segmented by seven major markets.
  • The Report also covers current Postoperative Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

COVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them

Retrieved on: 
Thursday, July 8, 2021
Pain, Branches of biology, Nervous system, Acute pain, Nociception, Pharmaceuticals policy, Suffering, Over-the-counter drug

With more people now treating themselves at home, increasing numbers have questions and concerns when it comes tousing over the counter medicines the right way.

Key Points: 
  • With more people now treating themselves at home, increasing numbers have questions and concerns when it comes tousing over the counter medicines the right way.
  • One area of health that is particularly in focus is the management of pain.
  • Pain is one of the most common medicalareas in which peopleseek information about ways toself-manage with medication.
  • You can find a lot of information online, but it is not always easy to know which sources to trust.

Global Pain Management Devices Market (2020 to 2026) - Featuring Baxter International, Boston Scientific and Stryker Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Medical devices, Health, Pain, Nervous system, Branches of biology, Acute pain, Nociception, Pain management, Palliative care

The increasing prevalence of chronic diseases along with the easy availability of technically advanced pain management devices in the market are the key factors to drive the growth of the global pain management devices market.

Key Points: 
  • The increasing prevalence of chronic diseases along with the easy availability of technically advanced pain management devices in the market are the key factors to drive the growth of the global pain management devices market.
  • The high cost of pain management devices, lack of awareness regarding the availability of pain management devices, insufficiency of a pain specialist in underdeveloped and some emerging economies are some key factors that may restrain the growth of the pain management devices market globally.
  • New product development is a prevalent trend in the pain management devices market.
  • The global pain management devices market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market.